Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 1
1991 1
1992 8
1993 3
1994 1
1995 1
1996 4
1997 5
1999 3
2000 9
2001 11
2002 9
2003 10
2004 6
2005 9
2006 4
2007 1
2008 3
2009 8
2010 5
2011 7
2012 7
2013 7
2014 3
2015 5
2016 3
2018 6
2019 1
2020 3
2021 2
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

140 results
Results by year
Filters applied: . Clear all
Page 1
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis.
Vannucchi AM, Kantarjian HM, Kiladjian JJ, Gotlib J, Cervantes F, Mesa RA, Sarlis NJ, Peng W, Sandor V, Gopalakrishna P, Hmissi A, Stalbovskaya V, Gupta V, Harrison C, Verstovsek S; COMFORT Investigators. Vannucchi AM, et al. Among authors: sarlis nj. Haematologica. 2015 Sep;100(9):1139-45. doi: 10.3324/haematol.2014.119545. Epub 2015 Jun 11. Haematologica. 2015. PMID: 26069290 Free PMC article. Clinical Trial.
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Lorch JH, Goloubeva O, Haddad RI, Cullen K, Sarlis N, Tishler R, Tan M, Fasciano J, Sammartino DE, Posner MR; TAX 324 Study Group. Lorch JH, et al. Among authors: sarlis n. Lancet Oncol. 2011 Feb;12(2):153-9. doi: 10.1016/S1470-2045(10)70279-5. Epub 2011 Jan 11. Lancet Oncol. 2011. PMID: 21233014 Free PMC article. Clinical Trial.
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Haddad R, O'Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, Clark J, Sarlis N, Lorch J, Beitler JJ, Limaye S, Riley S, Posner M. Haddad R, et al. Among authors: sarlis n. Lancet Oncol. 2013 Mar;14(3):257-64. doi: 10.1016/S1470-2045(13)70011-1. Epub 2013 Feb 13. Lancet Oncol. 2013. PMID: 23414589 Clinical Trial.
Thyroid and aging.
Habra M, Sarlis NJ. Habra M, et al. Among authors: sarlis nj. Rev Endocr Metab Disord. 2005 May;6(2):145-54. doi: 10.1007/s11154-005-1494-9. Rev Endocr Metab Disord. 2005. PMID: 15843886 Review. No abstract available.
Thyroid emergencies.
Sarlis NJ, Gourgiotis L. Sarlis NJ, et al. Rev Endocr Metab Disord. 2003 May;4(2):129-36. doi: 10.1023/a:1022933918182. Rev Endocr Metab Disord. 2003. PMID: 12766540 Review. No abstract available.
Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis.
Vaddi K, Sarlis NJ, Gupta V. Vaddi K, et al. Among authors: sarlis nj. Expert Opin Pharmacother. 2012 Nov;13(16):2397-407. doi: 10.1517/14656566.2012.732998. Epub 2012 Oct 10. Expert Opin Pharmacother. 2012. PMID: 23051187 Review.
140 results